{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:02:54Z","timestamp":1785301374285,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.7759\/cureus.113550","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:39:41Z","timestamp":1785299981000},"source":"Crossref","is-referenced-by-count":0,"title":["Third-Space Entrapment of Methotrexate in Anthracycline-Induced Cardiomyopathy: The First Complete Case Trajectory From Toxicity to Rescue Failure"],"prefix":"10.7759","author":[{"given":"Sanchit","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shahrukh","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salimah","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051459","article-title":"A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma","volume":"15","author":"Villanueva G","year":"2023","unstructured":"Villanueva G, Guscott M, Schaiquevich P, et al.. A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma. Cancers (Basel). 2023, 15:10.3390\/cancers15051459","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29518","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed KM","year":"2022","unstructured":"Hamed KM, Dighriri IM, Baomar AF, et al.. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022, 14:e29518. 10.7759\/cureus.29518","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101332","article-title":"Doxorubicin-induced cardiotoxicity and risk factors","volume":"50","author":"Belger C","year":"2024","unstructured":"Belger C, Abrahams C, Imamdin A, Lecour S. Doxorubicin-induced cardiotoxicity and risk factors. Int J Cardiol Heart Vasc. 2024, 50:101332. 10.1016\/j.ijcha.2023.101332","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-024-02467-6","article-title":"Periprosthetic seromas and a\u00a0third space effect after high-dose methotrexate","volume":"137","author":"Prattes C","year":"2025","unstructured":"Prattes C, Leithner A, Szkandera J, Prattes G, Urban EC, Eder-Halbedl A, Strenger V. Periprosthetic seromas and a\u00a0third space effect after high-dose methotrexate. Wien Klin Wochenschr. 2025, 137:537-43. 10.1007\/s00508-024-02467-6","journal-title":"Wien Klin Wochenschr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.32108","article-title":"Visceral fat and body fat as risk factors for methotrexate toxicity in pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"73","author":"Garc\u00eda-Guzm\u00e1n AD","year":"2026","unstructured":"Garc\u00eda-Guzm\u00e1n AD, Torreblanca-Garc\u00eda XM, Becerra-Morales SN, et al.. Visceral fat and body fat as risk factors for methotrexate toxicity in pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer. 2026, 73:e32108. 10.1002\/pbc.32108","journal-title":"Pediatr Blood Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee K","year":"2010","unstructured":"Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010, 115:155-62. 10.1159\/000265166","journal-title":"Cardiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.12.002","article-title":"From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach","volume":"4","author":"Minotti G","year":"2022","unstructured":"Minotti G, Reggiardo G, Camilli M, Salvatorelli E, Menna P. From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach. JACC CardioOncol. 2022, 4:139-40. 10.1016\/j.jaccao.2021.12.002","journal-title":"JACC CardioOncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v13.i1.28","article-title":"Anthracycline-induced cardiotoxicity: a case report and review of literature","volume":"13","author":"Chong EG","year":"2021","unstructured":"Chong EG, Lee EH, Sail R, Denham L, Nagaraj G, Hsueh CT. Anthracycline-induced cardiotoxicity: a case report and review of literature. World J Cardiol. 2021, 13:28-37. 10.4330\/wjc.v13.i1.28","journal-title":"World J Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier B","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al.. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010, 116:2040-5. 10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly H","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, et al.. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022, 386:351-63. 10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-440974","article-title":"Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma","volume":"121","author":"Rubenstein JL","year":"2013","unstructured":"Rubenstein JL, Li J, Chen L, et al.. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013, 121:745-51. 10.1182\/blood-2012-07-440974","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197823168","article-title":"Effect of pleural effusion on high-dose methotrexate kinetics","volume":"23","author":"Evans WE","year":"1978","unstructured":"Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther. 1978, 23:68-72. 10.1002\/cpt197823168","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-236554","article-title":"Common and external iliac artery occlusion in Beh\u00e7et's disease: a case of anchoring bias","volume":"13","author":"Khawaja H","year":"2020","unstructured":"Khawaja H, Font C. Common and external iliac artery occlusion in Beh\u00e7et's disease: a case of anchoring bias. BMJ Case Rep. 2020, 13:10.1136\/bcr-2020-236554","journal-title":"BMJ Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2020.07.012","article-title":"Bias in medicine: lessons learned and mitigation strategies","volume":"6","author":"Hammond ME","year":"2021","unstructured":"Hammond ME, Stehlik J, Drakos SG, Kfoury AG. Bias in medicine: lessons learned and mitigation strategies. JACC Basic Transl Sci. 2021, 6:78-85. 10.1016\/j.jacbts.2020.07.012","journal-title":"JACC Basic Transl Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25577","article-title":"Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction","volume":"62","author":"Widemann BC","year":"2015","unstructured":"Widemann BC. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction. Pediatr Blood Cancer. 2015, 62:1512-3. 10.1002\/pbc.25577","journal-title":"Pediatr Blood Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey LB","year":"2018","unstructured":"Ramsey LB, Balis FM, O'Brien MM, et al.. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018, 23:52-61. 10.1634\/theoncologist.2017-0243","journal-title":"Oncologist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08030621","article-title":"Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"17","author":"Ghannoum M","year":"2022","unstructured":"Ghannoum M, Roberts DM, Goldfarb DS, et al.. Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin J Am Soc Nephrol. 2022, 17:602-22. 10.2215\/CJN.08030621","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard SC","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016, 21:1471-82. 10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504648-third-space-entrapment-of-methotrexate-in-anthracycline-induced-cardiomyopathy-the-first-complete-case-trajectory-from-toxicity-to-rescue-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:39:53Z","timestamp":1785299993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504648-third-space-entrapment-of-methotrexate-in-anthracycline-induced-cardiomyopathy-the-first-complete-case-trajectory-from-toxicity-to-rescue-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.113550","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}